دورية أكاديمية
Highly efficient induced pluripotent stem cell reprogramming of cryopreserved lymphoblastoid cell lines.
| العنوان: | Highly efficient induced pluripotent stem cell reprogramming of cryopreserved lymphoblastoid cell lines. |
|---|---|
| المؤلفون: | Kumar S; Department of Human Genetics & South Texas Diabetes and Obesity Institute, University of Texas Rio Grande Valley School of Medicine, Edinburg and Brownsville, TX 78541, USA., Curran JE; Department of Human Genetics & South Texas Diabetes and Obesity Institute, University of Texas Rio Grande Valley School of Medicine, Edinburg and Brownsville, TX 78541, USA., Espinosa EC; Department of Human Genetics & South Texas Diabetes and Obesity Institute, University of Texas Rio Grande Valley School of Medicine, Edinburg and Brownsville, TX 78541, USA., Glahn DC; Olin Neuropsychiatry Research Center, The Institute of Living, Hartford, CT 06106, USA.; Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, USA., Blangero J; Department of Human Genetics & South Texas Diabetes and Obesity Institute, University of Texas Rio Grande Valley School of Medicine, Edinburg and Brownsville, TX 78541, USA. |
| المصدر: | Journal of biological methods [J Biol Methods] 2020 Jan 08; Vol. 7 (1), pp. e124. Date of Electronic Publication: 2020 Jan 08 (Print Publication: 2020). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: [POL Scientific, LLC] Country of Publication: United States NLM ID: 101639022 Publication Model: eCollection Cited Medium: Internet ISSN: 2326-9901 (Electronic) Linking ISSN: 23269901 NLM ISO Abbreviation: J Biol Methods Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [San Francisco, CA] : [POL Scientific, LLC], [2014]- |
| مستخلص: | Tissue culture based in-vitro experimental modeling of human inherited disorders provides insight into the cellular and molecular mechanisms involved and the underlying genetic component influencing the disease phenotype. The breakthrough development of induced pluripotent stem cell (iPSC) technology represents a quantum leap in experimental modeling of human diseases, providing investigators with a self-renewing and thus unlimited source of pluripotent cells for targeted differentiation into functionally relevant disease specific tissue/cell types. The existing rich bio-resource of Epstein-Barr virus (EBV) immortalized lymphoblastoid cell line (LCL) repositories generated from a wide array of patients in genetic and epidemiological studies worldwide, many of them with extensive genotypic, genomic and phenotypic data already existing, provides a great opportunity to reprogram iPSCs from any of these LCL donors in the context of their own genetic identity for disease modeling and disease gene identification. However, due to the low reprogramming efficiency and poor success rate of LCL to iPSC reprogramming, these LCL resources remain severely underused for this purpose. Here, we detailed step-by-step instructions to perform our highly efficient LCL-to-iPSC reprogramming protocol using EBNA1/OriP episomal plasmids encoding pluripotency transcription factors ( i.e. , OCT3/4, SOX2, KLF4, L-MYC, and LIN28), mouse p53DD (p53 carboxy-terminal dominant-negative fragment) and commercially available reprogramming media. We achieved a consistently high reprogramming efficiency and 100% success rate (> 200 reprogrammed iPSC lines) using this protocol. Competing Interests: Competing interests: The authors have declared that no competing interests exist. (© 2013-2020 The Journal of Biological Methods, All rights reserved.) |
| References: | Stem Cells Transl Med. 2014 Dec;3(12):1429-34. (PMID: 25298370) Stem Cells. 2011 Jun;29(6):992-1000. (PMID: 21563275) Stem Cells. 2013 Mar;31(3):458-66. (PMID: 23193063) Science. 1998 Nov 6;282(5391):1145-7. (PMID: 9804556) Nature. 1981 Jul 9;292(5819):154-6. (PMID: 7242681) Blood. 2011 Aug 18;118(7):1801-5. (PMID: 21628406) Exp Mol Med. 2015 Jan 23;47:e131. (PMID: 25613728) Nat Biotechnol. 2008 Nov;26(11):1276-84. (PMID: 18931654) Cell. 2007 Nov 30;131(5):861-72. (PMID: 18035408) J Virol. 1990 May;64(5):2309-18. (PMID: 2157887) Methods Mol Biol. 2018;1706:17-38. (PMID: 29423791) Stem Cells Int. 2016;2016:2349261. (PMID: 27375745) Nature. 2008 Jan 10;451(7175):141-6. (PMID: 18157115) Cell. 2006 Aug 25;126(4):663-76. (PMID: 16904174) Mol Cell. 2015 May 21;58(4):621-31. (PMID: 26000847) Blood. 2011 Aug 18;118(7):1797-800. (PMID: 21708888) Science. 2007 Dec 21;318(5858):1917-20. (PMID: 18029452) Oncogene. 2003 Aug 11;22(33):5108-21. (PMID: 12910248) EMBO J. 1987 Sep;6(9):2743-51. (PMID: 2824192) |
| معلومات مُعتمدة: | C06 RR020547 United States RR NCRR NIH HHS |
| فهرسة مساهمة: | Keywords: disease genetics; disease modeling; human; iPSC reprogramming; lymphoblastoid cell line |
| تواريخ الأحداث: | Date Created: 20200125 Latest Revision: 20200930 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC6974695 |
| DOI: | 10.14440/jbm.2020.296 |
| PMID: | 31976351 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2326-9901 |
|---|---|
| DOI: | 10.14440/jbm.2020.296 |